ArticleFrontiers in immunology2025
COL8A1 as a pro-inflammatory mediator bridges immune evasion and therapy resistance in glioma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma remains the most aggressive and therapy-resistant brain tumor, with a highly immunosuppressive tumor microenvironment. The role of inflammatory signaling in glioma progression and treatment response is poorly understood. Methods: We performed single-cell RNA sequencing (scRNA-seq) analysis on 93,027 cells from 18 samples. Inflammation-related genes were identified using hdWGCNA and AUCell scoring. Multiple bulk RNA-seq and microarray datasets were integrated for validation. Machine learning algorithms, including CoxBoost, LASSO, and Random Survival Forest, were used to identify prognostic genes. Immune infiltration, immunotherapy response, and mutational landscape were analyzed using established computational tools. Findings: COL8A1 was found to be a significant prognostic gene within a highly linked gene module connected to inflammation. Astrocytes, OPCs, and cancerous cells all had high levels of COL8A1 expression. In several cohorts, low survival was linked to high COL8A1 expression. The suppression of tumor migration and proliferation by COL8A1 knockdown was validated by functional tests. Multiple immunotherapy determinants, inhibitory immunological checkpoints, and immune cell infiltration all showed high correlations with COL8A1 expression. Additionally, it accurately forecasted the immune checkpoint blockade response. Through mutational profiling, we identified distinct somatic mutation patterns distinguishing COL8A1-high from COL8A1-low cancers. Conclusion: By connecting tumor-intrinsic inflammation to immunological surveillance and treatment resistance, our study identified COL8A1 as a crucial inflammatory hub in glioma. In order to improve the results of immunotherapy for glioma, COL8A1 may be a useful therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.